BNP Paribas Financial Markets Raises Position in Novo Nordisk A/S (NYSE:NVO)

BNP Paribas Financial Markets lifted its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 93.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 580,524 shares of the company's stock after acquiring an additional 280,541 shares during the period. BNP Paribas Financial Markets' holdings in Novo Nordisk A/S were worth $49,937,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Diversified Trust Co boosted its stake in Novo Nordisk A/S by 13.9% during the fourth quarter. Diversified Trust Co now owns 3,246 shares of the company's stock valued at $279,000 after buying an additional 395 shares during the last quarter. First Hawaiian Bank grew its stake in shares of Novo Nordisk A/S by 30.3% in the 4th quarter. First Hawaiian Bank now owns 22,259 shares of the company's stock worth $1,915,000 after buying an additional 5,171 shares in the last quarter. ORG Partners LLC increased its holdings in shares of Novo Nordisk A/S by 181.7% in the 4th quarter. ORG Partners LLC now owns 1,003 shares of the company's stock worth $86,000 after buying an additional 647 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its position in shares of Novo Nordisk A/S by 0.4% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 290,489 shares of the company's stock valued at $24,988,000 after buying an additional 1,051 shares in the last quarter. Finally, A. D. Beadell Investment Counsel Inc. lifted its holdings in shares of Novo Nordisk A/S by 41.1% in the 4th quarter. A. D. Beadell Investment Counsel Inc. now owns 13,012 shares of the company's stock valued at $1,119,000 after acquiring an additional 3,787 shares during the last quarter. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Up 1.4 %

Shares of NYSE:NVO traded up $0.90 during trading hours on Friday, hitting $65.75. The company's stock had a trading volume of 13,058,660 shares, compared to its average volume of 6,374,098. The company has a market capitalization of $295.06 billion, a price-to-earnings ratio of 19.98, a P/E/G ratio of 0.90 and a beta of 0.65. The firm's fifty day moving average price is $69.65 and its 200 day moving average price is $86.58. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. Novo Nordisk A/S has a 52 week low of $57.00 and a 52 week high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The firm had revenue of $11.87 billion during the quarter, compared to analysts' expectations of $79.17 billion. As a group, research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on NVO. Stifel Nicolaus downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Morgan Stanley began coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Dbs Bank cut shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. StockNews.com raised shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research report on Friday, April 25th. Finally, Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S has an average rating of "Moderate Buy" and a consensus price target of $135.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.